GlassScriptPhysician profile
Stacey Brock
NPI 1285370296
$2,002.26
in general payments reported to CMS, 2019-2025
38 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $165 · 2024: $758 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.27 |
| Education | $264.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $323.81 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $145.78 | 2023-2025 | Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $111.49 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Ipsen Biopharmaceuticals, INC | $99.00 | 2025 | |
| Gilead Sciences, INC. | $94.15 | 2024 | Trodelvy |
| Sanofi-Aventis U.S. LLC | $91.00 | 2024 | |
| Stemline Therapeutics INC. | $81.31 | 2024-2025 | Orserdu |
| Genmab U.S., INC. | $76.11 | 2023-2025 | Epkinly, Tivdak |
| Novartis Pharmaceuticals Corporation | $74.79 | 2025 | |
| Genzyme Corporation | $71.65 | 2023-2024 | |
| Glaxosmithkline, LLC. | $60.61 | 2024-2025 | Blenrep, Zejula, Jemperli |
| Janssen Biotech, INC. | $53.80 | 2024-2025 | Rybrevant, Tecvayli, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $49.99 | 2025 | |
| Jazz Pharmaceuticals INC. | $47.74 | 2024-2025 | |
| Eisai INC. | $41.99 | 2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $40.84 | 2025 | Opdivo |
| Incyte Corporation | $40.27 | 2024 | Monjuvi, Pemazyre, Jakafi |
| Pfizer INC. | $36.42 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $35.64 | 2025 | Libtayo |
| Emd Serono, INC. | $33.01 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $32.46 | 2023 | Imbruvica, Epkinly |
| Rigel Pharmaceuticals, INC. | $30.11 | 2023-2025 | Rezlidhia, Gavreto, Tavalisse |
| Fennec Pharmaceuticals, INC. | $29.26 | 2025 | Fyarro |
| Foundation Medicine, INC. | $24.73 | 2023 | |
| Pharmaessentia USA Corporation | $24.07 | 2025 | Besremi |
| Celgene Corporation | $23.67 | 2025 | Reblozyl |
| Iovance Biotherapeutics, INC. | $22.42 | 2025 | Amtagvi |
| Takeda Pharmaceuticals U.S.A., INC. | $21.89 | 2025 | Fruzaqla |
| Tempus Ai, INC | $21.33 | 2025 | Xt Cdx |
| Aveo Pharmaceuticals, INC. | $20.88 | 2025 | |
| Sobi, INC | $19.78 | 2024 | |
| Daiichi Sankyo INC. | $18.96 | 2024 | Enhertu |
| Array Biopharma INC | $18.64 | 2025 | Lorbrena |
| Lilly USA, LLC | $18.51 | 2024 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $17.42 | 2023 | Tukysa |
| Amgen INC. | $17.30 | 2023 | Lumakras |
| Legend Biotech USA INC. | $16.55 | 2024 | |
| Springworks Therapeutics, INC. | $14.88 | 2025 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Brock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.